68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour

[1] Mottet N(2016)EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent Eur Urol 65 124-137

[2] Bellmunt J(2014)EAU guidelines on prostate cancer: Part 1: screening, diagnosis, and local treatment with curative intent-update 2013 Eur Urol 70 233-245

[3] Bolla M(2016)Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis Eur Urol 50 29-32

[4] Briers E(2016)Validation of contemporary guidelines for bone scintigraphy in prostate cancer staging: a prospective study in patients undergoing radical prostatectomy Scand J Urol 4 173-184

[5] Cumberbatch MG(2009)PET imaging of prostate cancer using radiolabeled choline PET Clin 41 746-69

[6] De Santis M(2016)New clinical indications for (18)F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature Clin Nucl Med 43 55-2231

[7] Heidenreich A(2016)PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data Eur J Nucl Med Mol Imaging 41 2222-60

[8] Bastian PJ(2014)Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial Eur J Nucl Med Mol Imaging 59 51-23

[9] Bellmunt J(2011)The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer Eur Urol 21 12-495

[10] Bolla M(2014)Update on positron emission tomography for imaging of prostate cancer Int J Urol 40 486-209

[1] Mottet N(2016)EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent Eur Urol 65 124-137

[2] Bellmunt J(2014)EAU guidelines on prostate cancer: Part 1: screening, diagnosis, and local treatment with curative intent-update 2013 Eur Urol 70 233-245

[3] Bolla M(2016)Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis Eur Urol 50 29-32

[4] Briers E(2016)Validation of contemporary guidelines for bone scintigraphy in prostate cancer staging: a prospective study in patients undergoing radical prostatectomy Scand J Urol 4 173-184

[5] Cumberbatch MG(2009)PET imaging of prostate cancer using radiolabeled choline PET Clin 41 746-69

[6] De Santis M(2016)New clinical indications for (18)F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature Clin Nucl Med 43 55-2231

[7] Heidenreich A(2016)PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data Eur J Nucl Med Mol Imaging 41 2222-60

[8] Bastian PJ(2014)Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial Eur J Nucl Med Mol Imaging 59 51-23

[9] Bellmunt J(2011)The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer Eur Urol 21 12-495

[10] Bolla M(2014)Update on positron emission tomography for imaging of prostate cancer Int J Urol 40 486-209